|
Price: $3.6900
$0.02 
0.545%
|
| Day's High:
| $3.73
| Week Perf:
| 0.54 %
|
| Day's Low: |
$ 3.55 |
30 Day Perf: |
-10.22 % |
| Volume (M): |
507 |
52 Wk High: |
$ 6.09 |
| Volume (M$): |
$ 1,870 |
52 Wk Avg: |
$4.14 |
| Open: |
$3.64 |
52 Wk Low: |
$2.71 |
|
|
| Market Capitalization (Millions $) |
167 |
| Shares
Outstanding (Millions) |
45 |
| Employees |
17 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-37 |
| Cash Flow (TTM) (Millions $) |
-29 |
| Capital Exp. (TTM) (Millions $) |
0 |
Cormedix Inc
Cormedix Inc is a publicly traded pharmaceutical company based in Berkeley Heights, New Jersey, USA. The company was founded in 2006 by Dr. Ira Marks, a physician and medical researcher with over 25 years of clinical and drug development experience. Cormedix is dedicated to developing and commercializing innovative products for the prevention and treatment of infectious and inflammatory diseases.
Cormedix's flagship product is Neutrolin, a catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in hemodialysis patients. Neutrolin is a combination of three active ingredients: taurolidine, citrate, and heparin. Taurolidine is a broad-spectrum antimicrobial agent that kills bacteria, fungi, and viruses. Citrate is a potent anticoagulant that inhibits the formation of blood clots. Heparin is a common anticoagulant that prevents the formation of fibrin clots.
Neutrolin is currently undergoing phase 3 clinical trials in the USA and Europe. The results of the phase 2 trial were very positive, with a 70% reduction in CRBSIs compared to standard of care. The phase 3 trials are expected to be completed in 2021, and Cormedix plans to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) shortly thereafter. Neutrolin has received fast-track designation from the FDA, meaning that it will receive expedited review and approval.
Cormedix has a strong pipeline of other potential products, including a combination product for the treatment of diabetic foot infections and a taurolidine-based nasal spray for the prevention of COVID-19. The company has also developed a proprietary technology platform called the Hampden system, which uses microfluidics to simulate human physiology and disease. The Hampden system allows for rapid and cost-effective preclinical testing of new drug candidates.
Cormedix has a talented and experienced management team, including CEO Khoso Baluch, CFO Richard M. Cohen, and CMO Nahar Zaidi. The company has a market capitalization of approximately $135 million and is listed on the NASDAQ exchange under the ticker symbol CRMD. Cormedix has partnerships with several leading academic and research institutions, including the University of Toronto, the Mayo Clinic, and the University of California, San Francisco. The company is well-positioned to deliver innovative solutions to major unmet medical needs.
Company Address: 300 Connell Drive Berkeley Heights 7922 NJ
Company Phone Number: 517-9500 Stock Exchange / Ticker: NASDAQ CRMD
| CRMD is expected to report next financial results on November 09, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Immuron Limited
In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.
|
|
Procyon Corporation
Procyon Corporation recently released their financial results for the fourth quarter of the 2023 earnings season. While the company reported unaltered earnings per share (EPS), a decline in revenue and other key indicators raises concerns about the company's future performance. This article aims to interpret the financial results and discuss their potential impact on Procyon Corporation going forward.
1. Earnings per Share (EPS) and Revenue Performance:
Procyon Corporation maintained an EPS of $0.00 in the fourth quarter, suggesting stability in their profitability. However, the company experienced a modest revenue decline of -0.589% year-on-year, amounting to $1.20 million. This decline sets Procyon apart from the rest of the Major Pharmaceutical Preparations industry, which recorded a revenue improvement during the same period.
|
|
Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc, a pharmaceutical company, recently announced its financial results for the fiscal year ending June 30, 2023. During this period, the company achieved a break-even point of $0.00 per share, which was the same as the previous year and the previous quarter.
However, the company did not generate any revenue during this quarter, remaining at $0.00 million, the same as the previous year and quarter. This indicates that there was no growth in the company's revenue during this period.
Additionally, Innovation Pharmaceuticals Inc reported a net shortfall of $-0.681 million for the fiscal year ending June 30, 2023. This is a significant improvement compared to the deficit of $-1.626 million reported in the same quarter a year ago. Although still in a shortfall, the company has managed to reduce its losses, which may indicate positive efforts in managing their expenses.
|
|
Palatin Technologies Inc
Financial News Report:
Palatin Technologies Inc Reports Strong Revenue Growth in Q4 2023, Despite Stock Deficit
Palatin Technologies Inc (PTN) has announced a substantial revenue advancement of 109.038% year on year to $1.76 million in the fourth quarter of 2023. However, the company posted a deficit per stock at $-0.98. Despite the stock deficit, PTN's revenue experienced significant growth compared to its peers in the Major Pharmaceutical Preparations industry. Most corporations in this industry saw an average revenue advance of 3.04% during the same period.
In comparison to the preceding reporting period, PTN's revenue surged by 47.359% from $1.20 million and the deficit improved from $0.00 per share. This strong revenue growth indicates a positive trend for Palatin Technologies Inc.
|
|
Ibio Inc
In the aftermath of Ibio Inc's recently released fourth-quarter earnings report, the company appears to be grappling with mounting losses and a steep decline in its share value. The financial results for the quarter ended in 2023 revealed a concerning trend of escalating losses for the biotechnology firm.
Earnings Overview:
During the fourth quarter of the 2023 earnings season, Ibio Inc reported a significant increase in its loss per share compared to the same period in the prior year. The loss per share surged from $-0.10 a year ago to $-0.97, representing a substantial deterioration. Additionally, the company witnessed a sequential increase in losses, reaching $-0.55 per share from the previous financial reporting period.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.84 $ |
| Revenues (TTM) |
0 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.16 $
|
| Book Value |
1.08 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.84 $
|
| Revenues (TTM) |
0 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.16 $
|
| Book Value |
1.08 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
